Company intelligence / Profile preview

Xuan Jie Biotechnology

Taipei City, Taiwan

Ownership: Private
Development stage: Other

Overview

Xuan Jie Biotechnology has received regulatory approval to initiate Phase 2 clinical trials for its allogeneic umbilical cord mesenchymal stem cell drug (UMC119-06-05) in chronic obstructive pulmonary disease, and has progressed to emergency and clinical use for COVID-19 treatment and earlier stages for frailty and osteoarthritis[1][5].

Therapeutic areas: Infectious DiseasesRheumatologyPulmonologyOther
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Partnerships

Orilitia Biopharma Limited (Hong Kong)Shuanghe Hospital

Beyond the preview

Go deeper on Xuan Jie Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xuan Jie Biotechnology.

Explore the full profile